StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Free Report) in a research report released on Monday morning. The brokerage issued a sell rating on the stock.
Navidea Biopharmaceuticals Stock Performance
Shares of Navidea Biopharmaceuticals stock opened at $0.04 on Monday. Navidea Biopharmaceuticals has a twelve month low of $0.02 and a twelve month high of $0.22. The stock has a market cap of $3.60 million, a price-to-earnings ratio of -0.60 and a beta of 1.13. The company has a fifty day moving average price of $0.04 and a 200 day moving average price of $0.05.
About Navidea Biopharmaceuticals
Read More
- Five stocks we like better than Navidea Biopharmaceuticals
- Using the MarketBeat Dividend Tax Calculator
- AMD is Down 35%. Now is the Time to Buy the Dip
- What is a Secondary Public Offering? What Investors Need to Know
- Amazon Stands Tall: New Highs Are in Sight
- P/E Ratio Calculation: How to Assess Stocks
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.